Stay updated on Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial page.

Latest updates to the Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check14 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include a new revision number (v2.15.0) and references to COVID-19, while significant content regarding the study's objectives, inclusion and exclusion criteria, and study director information has been removed.SummaryDifference8%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check36 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check87 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
Stay in the know with updates to Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Remdesivir Safety & Antiviral Activity in Severe COVID-19 Clinical Trial page.